Iratumumab Completed Phase 2 Trials for Hodgkins Disease (HD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00284804A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease